AI-generated summary
This review article describes treatment options for primary cicatricial alopecias, a group of inflammatory conditions that cause permanent hair loss. The authors report that therapy is chosen by inflammatory pattern, with immunomodulatory agents used for lymphocytic forms and antimicrobials for neutrophilic forms, and that emerging options include metformin, JAK inhibitors and IL-17 or IL-23 biologics. Adjunctive modalities such as low-level light therapy and narrowband UVB are mentioned as complements to inflammation-directed care.
- Who or what was studied
- Patients with primary cicatricial alopecias (review article, not a patient study)
- Limits stated in the abstract
- The abstract states that no FDA-approved therapies exist and that all treatments are used off label, and it does not report the strength of supporting evidence.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Inflammation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.